Bolden Therapeutics

Bolden Therapeutics is an early-stage biotech focused on the challenging but high-potential field of therapeutic neurogenesis. The company has established preclinical proof-of-concept for its approach, demonstrating increased neurogenesis and enhanced memory in a proprietary mouse model. With a strong scientific foundation and a leadership team blending academic and venture expertise, Bolden is pursuing a multi-modality strategy against a broad range of neurological indications, including Alzheimer's disease, stroke recovery, and treatment-resistant depression. The company is currently in the pre-clinical development stage.

Platform targeting a novel signaling pathway to increase neurogenesis, with lead modality being exon-skipping antisense oligonucleotides (ASOs).

Direct competition in pharmacological neurogenesis is limited, making Bolden a pioneer. However, they compete indirectly with all companies developing therapies for cognitive disorders (e.g., Biogen, Eli Lilly in Alzheimer's) and must demonstrate superior or complementary efficacy. Other modalities like stem cell transplants also aim to add neurons but are more invasive.